Strides Pharma shares sold by 2 entities for Rs 81 crore

Published On 2024-02-10 08:00 GMT   |   Update On 2024-03-22 09:07 GMT

Bangalore: Two entities including Bajaj Finance have sold shares of Strides Pharma Science for Rs 81 crore through open market transactions. According to the block deal data available with the BSE, Bajaj Finance offloaded more than 8 lakh shares of Strides Pharma in two tranches and Shasun Leasing & Finance (promoter group entity of Strides Pharma) disposed of 3.35 lakh shares of...

Login or Register to read the full article

Bangalore: Two entities including Bajaj Finance have sold shares of Strides Pharma Science for Rs 81 crore through open market transactions. According to the block deal data available with the BSE, Bajaj Finance offloaded more than 8 lakh shares of Strides Pharma in two tranches and Shasun Leasing & Finance (promoter group entity of Strides Pharma) disposed of 3.35 lakh shares of the company.

Around 11.40 lakh shares were sold, which represents a 1.24 per cent stake in the company. The shares were sold at an average price of Rs 713 per piece, taking the combined transaction value to Rs 81.30 crore. Meanwhile, Amansa Holding acquired these shares at the same price. 

Read also: Strides Pharma Science Singapore arm gets USFDA okay for fibromyalgia drug Pregabalin

Recently, Promoters of Mankind Pharma has divested a 1.62 per cent stake in the company for Rs 1,367 crore through open market transactions.

Read also: Mankind Pharma promoters divest 1.6 percent stake worth Rs 1367 crore

Strides, a global pharmaceutical company headquartered in Bengaluru, India, is listed on the BSE Limited and National Stock Exchange of India Limited (STAR). The Company mainly operates in the regulated markets and has an “in Africa for Africa” strategy and an institutional business to service donor‐ funded markets. The Company’s global manufacturing sites are located in India (Chennai, Puducherry, and two locations in Bengaluru), Italy (Milan), Kenya (Nairobi) and the United States (New York).

Tags:    

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News